March 8, 2024 10:55 AM EST
News Briefing

In­ven­ti­va restarts PhI­II screen­ing for MASH tri­al; CD­MO an­nounces small pub­lic of­fer­ing

Ayisha Sharma

News Reporter

Anna Brown

News Reporter

Plus, news about Zymeworks:

In­ven­ti­va re­sumes screen­ing in PhI­II MASH tri­al: The biotech lift­ed a vol­un­tary pause it had placed on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times